All In Biotech

Drug Trial Radar · NCT04464967

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers

Last checked: Nov 19, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 2021

Primary completion

Aug 2022

Study completion Feb 2023

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
First posted
Jul 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.

Conditions

  • Advanced Solid Tumor
  • Metastatic Cancer
  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER-2 Protein Overexpression
  • Esophageal Cancer
  • Ovarian Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Non Small Cell Lung Cancer
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Triple Negative Breast Cancer
  • Cervical Cancer
  • Sarcoma

Interventions

  • SNK01Biological

    Patient-specific ex vivo expanded autologous natural killer cells

  • TrastuzumabDrug

    HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody

  • CetuximabDrug

    EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.Time frame: Up to 6 months
  2. Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.Time frame: Up to 6 months
  3. Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.Time frame: Up to 12 months
  4. Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.Time frame: Up to 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.